T1	Participants 121 149	acute promyelocytic leukemia
T2	Participants 199 233	acute promyelocytic leukemia (APL)
T3	Participants 703 883	previously untreated adult APL patients registered to protocol INT 0129 by the Eastern Cooperative Oncology Group, the Southwest Oncology Group, and the Cancer and Leukemia Group B
T4	Participants 885 984	Of 279 clinically eligible cases, 230 were molecularly evaluable, and of these, 111 were randomized
T5	Participants 1100 1179	Nine cases not excluded by central pathology review were PML-RAR alpha negative
